Abstract
Reduced bone mineral density (BMD) and increased rates of atraumatic fracture are observed in cystic fibrosis (CF) patients, causing increasing morbidity as this population ages. The study aimed to assess the safety, tolerability and effect on BMD of intravenous zoledronate in adults with CF and osteopenia.
Original language | English |
---|---|
Pages (from-to) | 838 - 846 |
Number of pages | 9 |
Journal | Clinical Endocrinology |
Volume | 70 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2009 |